Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$18.30
+0.9%
$20.24
$10.21
$25.67
$4.36B0.433.71 million shs1.05 million shs
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$65.29
+0.1%
$63.90
$52.50
$77.00
$1.41B0.57313,678 shs98,504 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.39
+0.2%
$2.24
$1.11
$17.88
$45.99M1.57509,172 shs191,018 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$79.21
-0.5%
$82.57
$73.11
$126.89
$5.56B0.121.02 million shs329,518 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.00%+0.74%-8.25%+1.58%+63.20%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
0.00%-0.32%+9.04%-3.30%+7.35%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
0.00%+13.79%-21.67%+82.76%-70.48%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.00%-2.80%-1.39%-12.88%-0.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.1393 of 5 stars
3.72.00.00.02.82.53.1
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.7139 of 5 stars
2.51.00.03.32.03.31.3
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
1.5144 of 5 stars
3.51.00.00.00.01.70.6
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.4425 of 5 stars
3.51.00.04.22.32.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6751.23% Upside
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$80.1322.72% Upside
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
3.00
Buy$18.00654.72% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$130.5064.75% Upside

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and LNTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
6/9/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $12.00
5/15/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $17.00
5/12/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
5/8/2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00
5/8/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $117.00
4/21/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$62.00 ➝ $65.00
4/11/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M10.24$0.54 per share33.77$1.48 per share12.36
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M2.30$7.60 per share8.59$19.11 per share3.42
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.67 per shareN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.57$6.99 per share11.34$15.65 per share5.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8521.5226.51N/A45.01%47.16%30.51%8/6/2025 (Estimated)
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.27N/A15.51N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5222.5012.55N/A16.55%36.99%20.55%7/30/2025 (Estimated)

Latest ANIP, ADMA, ANVS, and LNTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
5/13/2025Q1 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.47-$0.32+$0.15-$0.32N/AN/A
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
10.68
10.68
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%

Insider Ownership

CompanyInsider Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.50%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million230.38 millionOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million19.26 millionOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
319.49 million15.43 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million68.15 millionOptionable

Recent News About These Companies

Lantheus Seems Worth The (Very Real) Risks
Lantheus Holdings, Inc. (LNTH) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$18.30 +0.16 (+0.85%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$18.27 -0.03 (-0.14%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$65.29 +0.07 (+0.11%)
As of 07/3/2025 01:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.38 +0.01 (+0.21%)
Closing price 07/3/2025 03:50 PM Eastern
Extended Trading
$2.38 0.00 (0.00%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$79.21 -0.41 (-0.51%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$79.21 0.00 (0.00%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.